BMJ7d
EULAR recommendations for the treatment of systemic sclerosis: 2023 update
Objectives To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies. Methods An ...
BMJ12d
Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness
Objective Considering the diverse aetiologies and immunodysregulatory statuses observed in each patient with rheumatoid arthritis (RA), stratification based on peripheral blood immunophenotyping holds ...
BMJ1d
Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965–1996
OBJECTIVE To evaluate secular trends in the incidence and prevalence of rheumatoid arthritis (RA) in Japan. METHODS The incidence and prevalence of RA were determined in a longitudinal population ...
BMJ2d
Smoking and musculoskeletal disorders: findings from a British national survey
MRC Environmental Epidemiology Unit, Community Clinical Sciences, University of Southampton, UK Correspondence to: Dr K T Palmer, MRC Environmental Epidemiology Unit, Southampton General Hospital, ...
BMJ2d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
BMJ4d
Update of EULAR recommendations for the treatment of systemic sclerosis
The aim was to update the 2009 European League against Rheumatism (EULAR) recommendations for the treatment of systemic sclerosis (SSc), with attention to new therapeutic questions. Update of the ...
BMJ2d
Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups
Correspondence to Simon Rothwell, Centre for Genetics and Genomics, Arthritis Research UK, University of Manchester, Manchester M13 9PL, UK; s.rothwell{at}manchester.ac.uk Objectives Idiopathic ...
BMJ1d
Goodbye and thank you
Leo van de Putte, UMC Nijmegen, Nijmegen, PO Box 9101, 6500 HB, The Netherlands; l.vandeputte{at}reuma.umcn.nl If you wish to reuse any or all of this article please ...
BMJ2d
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology Unit, “Attikon” University Hospital, Athens 12462, Greece; afanour{at}med.uoa.gr Our objective was to update the EULAR ...
BMJ2d
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Correspondence to Dr Dimitrios T Boumpas, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Joint Academic Rheumatology Program, National ...
BMJ2d
Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial
1 Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody ...
BMJ1d
Role of nitric oxide in the regulation of T cell functions
Division of Immunology, Infection and Inflammation, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, UK Correspondence to: Professor F Y Liew Division of Immunology, Infection and ...